[
    "{\"step_by_step_thinking\": \"Document 0 states that TIM-3 is emerging as a therapeutic target for cancer immunotherapy and that it was an independent prognostic indicator for poor overall survival in cancer, including non-small cell lung carcinoma. Document 1 also mentions Tim-3 as a potential candidate for cancer immunotherapy. Document 2 highlights that targeting TIM-3 might be a promising approach for cancer immunotherapy. Document 3 suggests that the expression of TIM-3 in tumor cells may be a potential, independent prognostic factor for patients with NSCLC. Document 4 also supports targeting TIM-3 as a promising approach for improving current immunotherapy. These documents provide strong evidence that TIM-3 is a target for cancer immunotherapy in NSCLC.\", \"answer_choice\": \"A\"}"
]